IRIS
PENDE, ALDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.654
Totale 11.654
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.654
Totale 11.654
Salva come PNG Salva come JPEG
Città #
Genova 9.560
Rapallo 1.236
Genoa 807
Bordighera 51
Totale 11.654
Salva come PNG Salva come JPEG
Nome #
Lipoproteins, stroke and statins. 174
Characterization of the binding of the RNA-binding protein AUF1 to the human AT1 receptor mRNA. 150
Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis 148
Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. 142
Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways. 142
Angiotensin II receptor antagonists in acute coronary syndromes. 141
The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. 137
Plasma dopamine response to sympathetic activation in man: a biphasic pattern. 134
Inflammation in the pathophysiology of essential hypertension. 130
Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis 130
Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability 129
HPLC with electrochemical detection of catecholamines in human plasma, a mini-review. 128
Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. 126
Role of Neutrophils in Atherogenesis: an Update 126
Blunted response of serum aldosterone to metoclopramide in the male elderly 124
Inflammation Is a Key Pathophysiological Feature of Metabolic Syndrome. 123
Carotid atherosclerotic plaque stenosis: the stabilizing role of statins. 122
Prevalence of erectile dysfunction in a cohort of Italian hypertensive subjects 122
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis 122
Circadian variations of autologous mixed lymphocyte reactions and endogenous cortisol. 122
Anti-inflammatory approaches to reduce acute cardiovascular events: not only benefits. 121
Serum adiponectin levels predict acute coronary syndrome (ACS) in patients with severe carotid stenosis 121
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 121
Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. 120
Free and sulfoconjugated catecholamines in normotensive uremic patients: effects of hemodialysis. 119
Evidence for interactions between HLA system class I and beta-adrenergic receptors in human mononuclear leukocytes. 117
Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia 116
Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis 116
Morphine-induced TSH release in normal and hypothyroid subjects. 115
Update on the evidence of statin treatment to reduce plaque vulnerability. 115
Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages 115
Correlation between Progetto Cuore risk score and early cardiovascular damage in never treated subjects 113
Classical and new renin-angiotensin signalling in atherosclerosis. 112
Clorhexidine prevents hypoclorous acid-induced inactivation of alpha1-antitrypsin. 111
Serum lipoprotein (a) predicts acute coronary syndromes in patients with severe carotid stenosis 110
Inflammatory cardiovascular risk biomarkers: update on novelties and limitations. 110
Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. 109
Purification and characterization of b-adrenergic receptor mRNA-binding proteins. 108
Yohimbine effects on blood pressure and plasma catecholamines in human hypertension 106
Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk 106
Anti-ApoA-1 auto-antibodies increase cardiovascular vulnerability. 104
The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. 103
Resistin exerts a beneficial role in atherosclerotic plaque inflammation by inhibiting neutrophil migration 103
Baseline hs-CRP predicts hypertension remission in metabolic syndrome 102
Cardiovascular prevention: Can we do any better? 101
Neutrophil migration towards C5a and CXCL8 is abrogated by non-steroidal anti-inflammatory drugs (NSAIDs) via the inhibition of different pathways. 100
Evaluation of pituitary-thyroid function and prolactin secretion in healthy aged subjects. 99
Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. 99
Simultaneous measurement of plasma catecholamine (norepinephrine, epinephrine and dopamine) and free N-methyl dopamine (epinine) levels, by HPLC with electrochemical detection. 99
Carotid ultrasonography in the assessment of cardiovascular risk 97
Editorial: is ischemic stroke an inflammatory disease? 96
Epinine kinetics and plasma catecholamine changes following oral administration of the prodrug ibopamine in patients with chronic heart failure. 96
Agonist-mediated destabilization of human b1-adrenergic receptor mRNA: role of the 3’ untranslated region. 95
Anti-apoliprotein A-1 autoantibodies are active mediators of atherosclerotic plaque vulnerability. 95
Platelet-to-lymphocyte ratio at the time of carotid endarterectomy is associated with acute coronary syndrome occurrence 95
Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial 94
Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial 94
Myocardial-directed overexpression of the human b1-adrenergic receptor in transgenic mice. 92
Renin-Angiotensin antagonists: therapeutic effects beyond blood pressure control? 92
Regulation of the mRNA-binding protein AUF1 by activation of the b-adrenergic receptor signal transduction pathway. 91
Effects of the H2-receptor antagonist ranitidine on anterior pituitary hormone secretion in man. 90
Measurement of conjugated catecholamines in human plasma. A low cost HPLC ECD method. 89
Preliminary characterization of a transgenic mouse overexpressing the human b1-adrenergic receptor. 88
Effects of blood pressure control in cardiovascular prevention 88
Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study 88
Intraindividual variation of beta2-adrenergic receptors on mononuclear leukocytes and their relationships with endogenous plasma catecholamines in man. 87
Recombinant tissue plasminogen activator induces neutrophil degranulation activating PI3K/Akt- and ERK1/2-mediated pathways. 87
Identification and intracellular localization of RNA-binding proteins involved in the modulation of the hAT1 receptor mRNA stability. 86
Differential binding of p37AUF1 to beta-adrenergic receptor mRNAs. 85
Effect of clonidine on gonadotropin secretion in normal men. 84
Evidence for adrenergic mediation of the effect of morphine on LH secretion in normal men. 84
Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion and on cortisol secretion in normal men. 84
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial 84
Regulation of p37AUF1, an mRNA binding protein, in human ventricular myocardium. 83
Effects of rosuvastatin on atrial fibrillation occurrence: Ancillary results of the GISSI-HF trial 83
Syndrome of inappropriate antidiuretic hormone secretion and Ibuprofen, a rare association to be considered: role of tolvaptan. 81
Evaluation of some aspects of growth hormone regulation in aging. 81
Adrenergic receptors: relevance to myocardial signal transduction in heart failure. 81
Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation 81
Reversed-phase HPLC separation of plasma norepinephrine, epinephrine, and dopamine with three-electrode coulimetric detection. 80
Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study 80
Correlation between intrinsic mRNA stability and the affinity of AUF1 (hnRNPD) and HuR for A+U-rich mRNAs. 78
ß-adrenergic receptor mediated regulation of p37AUF1, an mRNA binding protein, in DDT1-MF2 cells. 77
Norepinephrine-induced plasma dopamine decrease in man: pharmacological evidence of the involvement of alpha2-adrenoceptors 77
Is the carotid plaque rupture a pivotal event in stroke pathogenesis? Update on the role of the intraplaque inflammatory processes 77
The 3’ untranslated region of the human beta1-adrenergic receptor is necessary but not sufficient for agonist-mediated destabilization. 76
Effects of Interferon alpha 2-a on catecholamines and lymphocyte beta2-adrenoceptors in healthy humans. 76
Neuroendocrine effects of Interferon alpha 2-a in healthy human subjects. 75
Regular Wine Consumption in Chronic Heart Failure: Impact on Outcomes, Quality of Life, and Circulating Biomarkers 75
Editorial: inhibition of the Renin-Angiotensin-aldosterone system: how to obtain this. 73
Effects of opioid substances on cAMP response to the beta-adrenergic agonist isoproterenol in human mononuclear leukocytes 72
Pituitary hormone secretion after inhibition of l-aromatic aminoacid decarboxylase. 72
Treatment with oxaprozin reduces neutrophil migration in response to C5a and CXCL8 via the inhibition of the PI3K/Akt pathway. 72
The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure 72
Interactions between HLA system and beta-adrenergic receptors in human lymphocytes. 71
Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Heart Failure trial 71
Immune and endocrine effects of a thymic extract in healthy human subjects. 70
Characterization of RNA-binding proteins possibly involved in modulating human AT 1 receptor mRNA stability. 70
Alpha-adrenergic control of TSH secretion in man. 69
Receptor activator of NF-kappa B ligand (RANKL) increases neutrophilic degranulation and potentially associated cardiovascular risk. 69
Totale 10.066
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.212
article - articoli 27.942
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.270
Totale 58.424
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019626 0 0 0 0 0 0 0 0 0 115 278 233
2019/20203.737 182 99 136 321 350 405 539 249 305 599 425 127
2020/20211.030 51 111 73 118 63 73 46 93 112 138 58 94
2021/20221.579 61 97 75 223 70 149 69 368 72 149 57 189
2022/20231.489 144 79 24 163 236 298 2 102 275 4 132 30
2023/2024613 26 128 23 77 66 95 56 81 47 14 0 0
Totale 11.920